Literature DB >> 11023623

Serum ferritin and death from all causes and cardiovascular disease: the NHANES II Mortality Study. National Health and Nutrition Examination Study.

C T Sempos1, A C Looker, R E Gillum, D L McGee, C V Vuong, C L Johnson.   

Abstract

PURPOSE: The purpose of this study was to assess the association between serum ferritin and death from all causes, cardiovascular diseases (CVD), CHD and myocardial infarction (MI). Positive body iron stores have been proposed as a risk factor for coronary heart disease (CHD). While most epidemiologic studies using serum ferritin and other measures of body iron stores have not found an association between iron and heart disease risk, the hypothesis remains controversial. As a result, we examined the relationship of serum ferritin, the principle blood measure of body iron stores, to risk of death in a cohort with a standardized exam and long follow-up.
METHODS: The baseline data for this prospective cohort study were collected in 1976-1980 as part of the second National Health and Nutrition Examination Study (NHANES II) with mortality follow-up using the National Death Index (NDI) through December 31, 1992. The analytic sample (n = 1604) consisted of 128 black men, 658 white men, 100 black women and 718 white women 45-74 years of age at baseline who, based on self-reported data, were free of coronary heart disease at baseline and had no missing data. The main outcome measures were the relative risk of death for persons with serum ferritin levels: <50 microg/L; or 100-199 microg/L; or > or =200 microg/L was compared to persons with serum ferritin levels of 50-99 microg/L adjusted for possible confounding using the Cox proportional hazards model.
RESULTS: Most of the deaths were among white men (n = 254) and women (n = 168). There were relatively few deaths among black men (n = 50) and too few in women (n = 23) to reliably model. The largest number of CVD (n = 119), CHD (n = 82), and MI (n = 49) deaths were in white men while there were 69 CVD, 45 CHD and 13 MI deaths in white women. Black men with a serum ferritin level of <50 microg/L had a significantly higher adjusted risk of death from all causes (RR = 3.1 with 95% confidence limits of 1.5-6.5). There were no other statistically significant associations for all causes mortality for the other three race/sex groups. Additionally, there were no statistically significant associations between serum ferritin and any of the cardiovascular endpoints for any of the groups. There was an apparent but nonsignificant u-shaped association between serum ferritin and all causes mortality in black men and between serum ferritin and CVD death in white women. However, in both cases very wide confidence limits preclude further interpretation.
CONCLUSIONS: Overall, the results do not support the hypothesis that positive body iron stores, as measured by serum ferritin, are associated with an increased risk of CVD, CHD or MI death or between serum ferritin and all causes mortality. Most of the research to date with serum ferritin has been conducted in European men or in European American men. Our results are consistent with the primarily negative results for that race/sex group. More research is needed in women and minority groups, including an explanation of why such an association would exist in these groups but not in white men before an association can be established in them.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11023623     DOI: 10.1016/s1047-2797(00)00068-5

Source DB:  PubMed          Journal:  Ann Epidemiol        ISSN: 1047-2797            Impact factor:   3.797


  30 in total

1.  The prevalence of haemochromatosis gene mutations in the West of Scotland and their relation to ischaemic heart disease.

Authors:  S Campbell; D K George; S D Robb; R Spooner; T A McDonagh; H J Dargie; P R Mills
Journal:  Heart       Date:  2003-09       Impact factor: 5.994

2.  Excessive body iron stores are not associated with risk of coronary heart disease in women.

Authors:  Qi Sun; Jing Ma; Nader Rifai; Oscar H Franco; Kathryn M Rexrode; Frank B Hu
Journal:  J Nutr       Date:  2008-12       Impact factor: 4.798

3.  Leukocyte telomere length: the telomere tale continues.

Authors:  Abraham Aviv
Journal:  Am J Clin Nutr       Date:  2009-04-22       Impact factor: 7.045

Review 4.  Iron deficiency and cardiovascular disease: an updated review of the evidence.

Authors:  Emanuela Lapice; Maria Masulli; Olga Vaccaro
Journal:  Curr Atheroscler Rep       Date:  2013-10       Impact factor: 5.113

5.  Frequency of cardiovascular events in patients treated with anti hypertensive agents: A cohort study based on claims data generated by primary care practice.

Authors:  Pierluigi Russo; Alessandro Capone; Alessandra Sturani; Ezio Degli Esposti
Journal:  Curr Ther Res Clin Exp       Date:  2004-09

6.  Dietary iron intake and body iron stores are associated with risk of coronary heart disease in a meta-analysis of prospective cohort studies.

Authors:  Jacob Hunnicutt; Ka He; Pengcheng Xun
Journal:  J Nutr       Date:  2014-01-08       Impact factor: 4.798

7.  Iron replacement therapy in the routine management of blood donors.

Authors:  Barbara J Bryant; Yu Ying Yau; Sarah M Arceo; Jennifer Daniel-Johnson; Julie A Hopkins; Susan F Leitman
Journal:  Transfusion       Date:  2011-12-29       Impact factor: 3.157

8.  Serum ferritin is an independent factor in coronary artery stenosis among hemodialysis patients.

Authors:  Chen-Tung Lien; Chiang-Chin Tsai; Chien-An Chen; Chieh Kuo; Meng-Yi Tsai
Journal:  Int J Hematol       Date:  2016-06-21       Impact factor: 2.490

9.  Iron status is associated with carotid atherosclerotic plaques in middle-aged adults.

Authors:  Namanjeet Ahluwalia; Annelise Genoux; Jean Ferrieres; Bertrand Perret; Marion Carayol; Ludovic Drouet; Jean-Bernard Ruidavets
Journal:  J Nutr       Date:  2010-02-24       Impact factor: 4.798

10.  The association of biomarkers of iron status with peripheral arterial disease in US adults.

Authors:  Andy Menke; José Manuel Fernández-Real; Paul Muntner; Eliseo Guallar
Journal:  BMC Cardiovasc Disord       Date:  2009-08-03       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.